The EXAMINE trial (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) was a landmark cardiovascular outcomes trial designed to assess the safety of alogliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, in patients with type 2 diabetes who had a recent history of acute coronary syndrome (ACS). The gene discussed is DPP4; the disease is acute coronary syndrome.